D. Parker Kelley, PhD is a postdoctoral data science fellow in trauma and PTSD research at the San Francisco VA in the trauma and health research on immunity, vitality, and emotions (THRIVE) lab, and at the University of California, San Francisco (UCSF) in the Translational Psychedelic Research Program (TrPR). He earned a B.A. in physiological psychology, a B.S. in philosophy of mind, and a PhD in Biomedical Sciences at Louisiana State University (LSU) split between the School of Veterinary Medicine and LSU Health Sciences Center. During his graduate training, he focused on the role of allostatic load-associated factors in animal models of stress and trauma, and the behavioral and molecular pharmacology of DMT, pharmahuasca, and other psychedelic drugs. At THRIVE, Dr. Kelley is applying mitochondrial psychobiological and psychoneuroimmunological approaches to the study of PTSD and other psychiatric disorders, and has recently developed the allostatic triage model of psychopathology (ATP Model), which explains transdiagnostic psychopathogenesis from a bioenergetic perspective. At TrPR, Dr. Kelley is studying the putative therapeutic effects of psychedelic 5-HT2AR agonists through the lens of mitochondrial psychobiology, and has developed a novel model called 2A Allostatic Recalibration Theory (2A-ART) that explains how psychedelic drugs produce transdiagnostic therapeutic effects.

—

Are psychedelics anti-inflammatory?  A systematic review and meta-analysis of studies examining the immunomodulatory effects of serotonergic psychedelics